Publications
Rugo HS, Gelmon K. Use of Neoadjuvant Platinum-The Ongoing Conundrum. JAMA oncology. 2017. PMID: 28715579
Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. Journal of Crohn's & colitis. 2017. PMID: 28605483
Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Human reproduction (Oxford, England). 2017. PMID: 28938748
Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Familial cancer. 2017. PMID: 28283864
Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Annals of oncology : official journal of the European Society for Medical Oncology. 2017. PMID: 28945843
Gajewski JL, McClellan MB, Majhail NS, Hari PN, Bredeson CN, Maziarz RT, LeMaistre CF, Lill MC, Farnia SH, Komanduri KV, Boo MJ. Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017. PMID: 28963077
Mayekar MK, Bivona TG. Current Landscape of Targeted Therapy in Lung Cancer. Clinical pharmacology and therapeutics. 2017. PMID: 28786099
Ramstein JJ, Tsai KK, Smith JF. Tyrosine Kinase Inhibitors and Male Reproductive Health. Clinical pharmacology and therapeutics. 2017. PMID: 28791688
Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI insight. 2017. PMID: 28931755
Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. The oncologist. 2017. PMID: 28935773
Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. The oncologist. 2017. PMID: 28935773
Brzezniak C, Oronsky B, Aggarwal R. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. European urology. 2017. PMID: 28943185
Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral oncology. 2017. PMID: 29103750
Peters BA, Park JW, Drmanac R. Pure CTCs, advanced WGS, and precise personalized combination therapies. Oncoscience. 2017. PMID: 28966939
Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI research. 2017. PMID: 28929350
Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. Journal for immunotherapy of cancer. 2017. PMID: 28923100
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nature reviews. Clinical oncology. 2017. PMID: 28925994
Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlar C, Khan I, Doshi P, Usmani S. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2017. PMID: 29054515
Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017. PMID: 28924018
Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017. PMID: 28924018